Long-Term Safety and Efficacy Extension Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00835770
First received: February 2, 2009
Last updated: October 3, 2014
Last verified: October 2014
  Purpose

The primary objective of this study is to evaluate the long-term safety and efficacy of BG00012. Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301(NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.


Condition Intervention Phase
Relapsing-Remitting Multiple Sclerosis
Drug: BG00012
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • Number of Participants with Adverse Events [ Time Frame: Up to 8 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of Participants Who Had Relapses [ Time Frame: Day 1 up to 8 years ] [ Designated as safety issue: No ]
  • Annualized Relapse Rate (ARR) [ Time Frame: Day 1 up to 8 years ] [ Designated as safety issue: No ]
  • Change from Baseline in the Expanded Disability Status Scale (EDSS) up to 8 years [ Time Frame: Day 1 (baseline), up to 8 years ] [ Designated as safety issue: No ]
    Progression of disability is defined as at least a 1.0 point increase on the EDSS from baseline EDSS 1.0 that is sustained for 24 weeks or at least a 1.5 point increase on the EDSS from baseline EDSS =0 that is sustained for 24 weeks.

  • Number and volume of Gd-enhancing lesions as Measured by Magnetic Resonance Imaging (MRI) [ Time Frame: Day 1 up to 8 years ] [ Designated as safety issue: No ]
  • Number and volume of new or newly-enlarging T2 lesions as Measured by Magnetic Resonance Imaging (MRI) [ Time Frame: Day 1 up to 8 years ] [ Designated as safety issue: No ]
  • Number and volume of T1 hypointense lesions [ Time Frame: Day 1 up to 8 years ] [ Designated as safety issue: No ]
  • Change from Baseline in Brain atrophy up to 8 years [ Time Frame: Day 1 (baseline), up to 8 years ] [ Designated as safety issue: No ]
  • Summary of Magnetization Transfer Ratio (MTR) [ Time Frame: Day 1 up to 8 years ] [ Designated as safety issue: No ]
    MTR is used in neuroradiology to highlight abnormalities in brain structures

  • Change from Baseline in EQ-5D Health Survey (EQ-5D) up to 8 years [ Time Frame: Day 1 (baseline), up to 8 years ] [ Designated as safety issue: No ]
    EQ-5D measures quality of life.

  • Change from baseline in SF-36® Health Survey (SF-36) up to 8 years [ Time Frame: Day 1 (baseline), up to 8 years ] [ Designated as safety issue: No ]
  • Change from Baseline in Visual Function test scores up to 8 years [ Time Frame: Day 1 (baseline), up to 8 years ] [ Designated as safety issue: No ]

Enrollment: 1738
Study Start Date: February 2009
Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BG00012 240 mg BID
In the first phase, participants will receive BG00012 240 mg twice a day (BID; two 120 mg capsules twice a day) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for up to 8 years.
Drug: BG00012
BG00012 capsules
Other Names:
  • oral fumarate
  • BG-12
Drug: Placebo
Capsules taken to maintain the blind in the 240 mg BID treatment group.
Experimental: BG00012 240 mg TID
In the first phase participants will receive BG00012 240 mg three times a day (TID) . In the second phase participants will receive open-label BG00012 240 mg BID for up to 8 years.
Drug: BG00012
BG00012 capsules
Other Names:
  • oral fumarate
  • BG-12

Detailed Description:

The initial BG00012 dosage for the extension study (240 mg BID or 240 mg TID) was the same as that used in the Phase 3 Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451). Subsequent to the initiation of this study, BG00012 was approved in several countries for the treatment of MS at a dose of 240 mg BID. For this reason, all participants continuing in this study at the time Protocol Version 3 is implemented will receive the currently marketed dose of 240 mg BID. Upon approval of Protocol Version 3, participants currently receiving BG00012 240 mg TID will be switched to BID dosing at their next scheduled visit.

  Eligibility

Ages Eligible for Study:   19 Years to 58 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

-Subjects who participated in and completed as per protocol previous BG00012 clinical studies 109MS301 (NCT00420212) or 109MS302 (NCT00451451).

Key Exclusion Criteria:

  • Any significant change in medical history from 109MS301 or 109MS302 that would have excluded subject's participation from their previous study.
  • Subjects from 109MS301 or 109MS302 who discontinued oral study treatment due to an AE or due to reasons other than protocol-defined relapse/disability progression.
  • Subjects from 109MS301 or 109MS302 who discontinued study treatment due to disability progression or relapses and did not follow the modified visit schedule up to Week 96.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00835770

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
Research Site
Huntsville, Alabama, United States
United States, Arizona
Research Site
Gilbert, Arizona, United States
Research Site
Phoenix, Arizona, United States
United States, California
Research Site
Loma Linda, California, United States
Research Site
Sacramento, California, United States
United States, Colorado
Research Site
Boulder, Colorado, United States
Research Site
Colorado Springs, Colorado, United States
Research Site
Fort Collins, Colorado, United States
United States, Connecticut
Research Site
Fairfield, Connecticut, United States
United States, District of Columbia
Research Site
Washington, District of Columbia, United States
United States, Florida
Research Site
Maitland, Florida, United States
Research Site
Naples, Florida, United States
Research Site
Saint Petersburg, Florida, United States
Research Site
Sarasota, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Vero Beach, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
United States, Illinois
Research Site
Evanston, Illinois, United States
United States, Indiana
Research Site
Fort Wayne, Indiana, United States
Research Site
Indianapolis, Indiana, United States
United States, Iowa
Research Site
Des Moines, Iowa, United States
United States, Kansas
Research Site
Kansas City, Kansas, United States
Research Site
Wichita, Kansas, United States
United States, Kentucky
Research Site
Lexington, Kentucky, United States
Research Site
Louisville, Kentucky, United States
United States, Louisiana
Research Site
Shreveport, Louisiana, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
Research Site
Hopedale, Massachusetts, United States
Research Site
Springfield, Massachusetts, United States
United States, Michigan
Research Site
Farmington Hills, Michigan, United States
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States
United States, Missouri
Research Site
Saint Louis, Missouri, United States
United States, New York
Research Site
Albany, New York, United States
Research Site
Amherst, New York, United States
Research Site
Buffalo, New York, United States
Research Site
Patchogue, New York, United States
United States, North Carolina
Research Site
Charlotte, North Carolina, United States
Research Site
Raleigh, North Carolina, United States
United States, Ohio
Research Site
Bellevue, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Columbus, Ohio, United States
Research Site
Dayton, Ohio, United States
United States, Oregon
Research Site
Medford, Oregon, United States
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Erie, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburg, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Research Site
East Providence, Rhode Island, United States
United States, Tennessee
Research Site
Cordova, Tennessee, United States
Research Site
Franklin, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
United States, Vermont
Research Site
Burlington, Vermont, United States
United States, Virginia
Research Site
Newport News, Virginia, United States
United States, Washington
Research Site
Seattle, Washington, United States
Research Site
Tacoma, Washington, United States
United States, Wisconsin
Research Site
Madison, Wisconsin, United States
Australia, New South Wales
Research Site
Camperdown, New South Wales, Australia
Research Site
Chatswood, New South Wales, Australia
Research Site
Kogarah, New South Wales, Australia
Research Site
New Lambton Heights, New South Wales, Australia
Australia, Victoria
Research Site
Fitzroy, Victoria, Australia
Research Site
West Heidelberg, Victoria, Australia
Austria
Research Site
Graz, Styria, Austria
Research Site
Linz, Upper Austria, Austria
Research Site
Wien, Vienna, Austria
Canada, Alberta
Research Site
Edmonton, Alberta, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
London, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Canada, Quebec
Research Site
Lévis, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Canada, Saskatchewan
Research Site
Regina, Saskatchewan, Canada
Croatia
Research Site
Zagreb, Croatia
Czech Republic
Research Site
Brno, Jihocesky Kraj, Czech Republic
Research Site
Jihlava, Kraj Vysocina, Czech Republic
Research Site
Olomouc, Olomoucký kraj, Czech Republic
Research Site
Praha 5, Praha, Czech Republic
Research Site
Teplice, Severocesky Kraj, Czech Republic
Research Site
Opava, Czech Republic
Research Site
Ostrava - Vítkovice, Czech Republic
Research Site
Ostrava-Moravska Ostrava, Czech Republic
Research Site
Praha 2, Czech Republic
Estonia
Research Site
Parnu, Estonia
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Germany
Research Site
Bamberg, Bayern, Germany
Research Site
Erlangen, Bayern, Germany
Research Site
München, Bayern, Germany
Research Site
Regensburg, Bayern, Germany
Research Site
Hannover, Niedersachsen, Germany
Research Site
Osnabrück, Niedersachsen, Germany
Research Site
Westerstede, Niedersachsen, Germany
Research Site
Bochum, Nordrhein-westfalen, Germany
Research Site
Düsseldorf, Nordrhein-westfalen, Germany
Research Site
Essen, Nordrhein-westfalen, Germany
Research Site
Minden, Nordrhein-westfalen, Germany
Research Site
Halle, Sachsen-anhalt, Germany
Research Site
Dresden, Sachsen, Germany
Research Site
Leipzig, Sachsen, Germany
Research Site
Berlin, Germany
Research Site
Erbach, Germany
Research Site
Hamburg, Germany
Greece
Research Site
Athens, Attica, Greece
Research Site
Thessaloniki, Macedoni, Greece
Guatemala
Research Site
Guatemala, Guatemala
Research Site
Guatemala City, Guatemala
Italy
Research Site
Roma, Italy
Latvia
Research Site
Riga, Latvia
Mexico
Research Site
Mexico, Distrito Federal, Mexico
Research Site
San Luis Potosi, Mexico
Netherlands
Research Site
Sittard-Geleen, Limburg, Netherlands
New Zealand
Research Site
Grafton, Auckland, New Zealand
Research Site
Christchurch, New Zealand
Research Site
Hamilton, New Zealand
Poland
Research Site
Wroclaw, Dolnoslaskie, Poland
Research Site
Lódz, Lodzkie, Poland
Research Site
Warszawa, Mazowieckie, Poland
Research Site
Bialystok, Podlaskie, Poland
Research Site
Gdansk, Pomorskie, Poland
Research Site
Katowice, Slaskie, Poland
Research Site
Plewiska K/Poznania, Wielkopolskie, Poland
Research Site
Szczecin, Zachodniopomorskie, Poland
Research Site
Lublin, Poland
Puerto Rico
Research Site
Guaynabo, Puerto Rico
Romania
Research Site
Cluj-Napoca, Cluj, Romania
Research Site
Târgu Mures, Mures, Romania
Research Site
Timisoara, Timis, Romania
Research Site
Bucuresti, Romania
Serbia
Research Site
Kragujevac, Serbia
Research Site
Nis, Serbia
Slovakia
Research Site
Bratislava, Slovakia
Research Site
Martin, Žilina, Slovakia
South Africa
Research Site
Rosebank, Gauteng, South Africa
Research Site
Durban, KwaZulu-Natal, South Africa
Research Site
Cape Town, Western Cape, South Africa
Spain
Research Site
Sevilla, Andalucía, Spain
Research Site
Córdoba, Cordoba, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Switzerland
Research Site
Basel, Switzerland
Ukraine
Research Site
Simferopol, Crimea, Ukraine
Research Site
Kyiv, Kiev, Ukraine
Research Site
Kharkiv, Ukraine
Research Site
Kyiv, Ukraine
Research Site
Lviv, Ukraine
Research Site
Odessa, Ukraine
United Kingdom
Research Site
London, England, United Kingdom
Research Site
Newcastle upon Tyne, England, United Kingdom
Research Site
Oxford, England, United Kingdom
Research Site
Sheffield, England, United Kingdom
Research Site
Staffordshire, England, United Kingdom
Sponsors and Collaborators
Biogen Idec
Investigators
Study Director: Medical Director Biogen Idec
  More Information

No publications provided

Responsible Party: Biogen Idec
ClinicalTrials.gov Identifier: NCT00835770     History of Changes
Other Study ID Numbers: 109MS303
Study First Received: February 2, 2009
Last Updated: October 3, 2014
Health Authority: Israel: Ministry of Health
Belgium: Federal Agency for Medicinal Products and Health Products
Romania: National Medicines Agency
Bulgaria: Bulgarian Drug Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Switzerland: Swissmedic
Ukraine: State Pharmacological Center - Ministry of Health
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Ireland: Irish Medicines Board
Macedonia: Ministry of Health
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Guatemala: Ministry of Public Health and Social Assistance
Australia: Department of Health and Ageing Therapeutic Goods Administration
New Zealand: Ministry of Health
Bosnia: Federal Ministry of Health
Italy: Ministry of Health
Estonia: The State Agency of Medicine
Austria: Agency for Health and Food Safety
South Africa: Medicines Control Council
Czech Republic: State Institute for Drug Control
Greece: National Organization of Medicines
Slovakia: State Institute for Drug Control
Mexico: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices
Serbia and Montenegro: Agency for Drugs and Medicinal Devices
Croatia: Ministry of Health and Social Care
Belarus: Ministry of Health
Canada: Health Canada
Latvia: State Agency of Medicines
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
United States: Food and Drug Administration
India: Drugs Controller General of India
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Moldova: Ministry of Health

Keywords provided by Biogen Idec:
relapsing
multiple sclerosis
remitting
oral

Additional relevant MeSH terms:
Dimethyl fumarate
Sclerosis
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on October 16, 2014